Disorder of plasmalogens biosynthesis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3276
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Disorders of plasmalogen biosynthesis, also known as plasmalogen deficiency or plasmalogen synthesis defects, are a group of rare inherited metabolic conditions in which the body cannot properly produce plasmalogens — a specialized class of ether phospholipids that are critical components of cell membranes, particularly abundant in the brain, heart, lungs, and kidneys. Plasmalogens play important roles in membrane structure, antioxidant defense, and cellular signaling. The most well-characterized disorders of plasmalogen biosynthesis are the rhizomelic chondrodysplasia punctata (RCDP) spectrum, caused by defects in peroxisomal enzymes involved in the plasmalogen synthesis pathway, including GNPAT (dihydroxyacetone phosphate acyltransferase), AGPS (alkyldihydroxyacetone phosphate synthase), and PEX7 (peroxisomal biogenesis factor 7). Clinical features typically manifest at birth or in early infancy and may include severe skeletal abnormalities such as rhizomelic (proximal) limb shortening, stippled calcifications of cartilage (chondrodysplasia punctata), cataracts, profound intellectual disability, growth failure, seizures, and ichthyosis (dry, scaly skin). The severity of the condition varies depending on the specific genetic defect and the degree of residual plasmalogen synthesis. Many affected individuals have a significantly shortened lifespan, with severe forms often leading to death in infancy or early childhood, though milder phenotypes with longer survival have been described. Currently, there is no curative treatment for disorders of plasmalogen biosynthesis. Management is supportive and multidisciplinary, focusing on nutritional support, physical therapy, orthopedic interventions for skeletal complications, ophthalmologic care for cataracts, and seizure management. Research into plasmalogen replacement therapy and other experimental approaches is ongoing but remains in early stages. Genetic counseling is recommended for affected families.

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Disorder of plasmalogens biosynthesis.

View clinical trials →

No actively recruiting trials found for Disorder of plasmalogens biosynthesis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Disorder of plasmalogens biosynthesis community →

No specialists are currently listed for Disorder of plasmalogens biosynthesis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Disorder of plasmalogens biosynthesis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Disorder of plasmalogens biosynthesisForum →

No community posts yet. Be the first to share your experience with Disorder of plasmalogens biosynthesis.

Start the conversation →

Latest news about Disorder of plasmalogens biosynthesis

No recent news articles for Disorder of plasmalogens biosynthesis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Disorder of plasmalogens biosynthesis

What is Disorder of plasmalogens biosynthesis?

Disorders of plasmalogen biosynthesis, also known as plasmalogen deficiency or plasmalogen synthesis defects, are a group of rare inherited metabolic conditions in which the body cannot properly produce plasmalogens — a specialized class of ether phospholipids that are critical components of cell membranes, particularly abundant in the brain, heart, lungs, and kidneys. Plasmalogens play important roles in membrane structure, antioxidant defense, and cellular signaling. The most well-characterized disorders of plasmalogen biosynthesis are the rhizomelic chondrodysplasia punctata (RCDP) spectrum

How is Disorder of plasmalogens biosynthesis inherited?

Disorder of plasmalogens biosynthesis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Disorder of plasmalogens biosynthesis typically begin?

Typical onset of Disorder of plasmalogens biosynthesis is neonatal. Age of onset can vary across affected individuals.